Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference
15 May 2021 - 6:01AM
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage
biotechnology company pioneering a precision medicine approach for
the discovery, development, and commercialization of novel
therapeutic and companion diagnostic products for the treatment of
immune-mediated diseases, starting first with inflammatory bowel
disease (IBD), today announced that Mark McKenna, President and
CEO, will participate virtually in a fireside chat during the 2021
RBC Capital Markets Global Healthcare Conference on Wednesday, May
19, 2021 at 10:55 a.m. ET.
A live and archived webcast of the virtual
fireside chat will be available via the Events section of the
Prometheus Biosciences website.
About Prometheus Biosciences
Prometheus Biosciences, Inc. is a clinical-stage biotechnology
company pioneering a precision medicine approach for the discovery,
development, and commercialization of novel therapeutic and
companion diagnostic products for the treatment and diagnosis of
immune-mediated diseases, starting first with IBD. The
Company’s precision medicine platform, Prometheus360, combines
proprietary bioinformatics discovery methods with one of the
world’s largest gastrointestinal bioinformatics databases to
identify novel therapeutic targets and develop therapeutic
candidates to engage those targets. Prometheus is
headquartered in San Diego, CA.
Contacts:Noel KurdiVP Investor Relations and
Communications(646)
241-4400nkurdi@prometheusbiosciences.com
Media contact:Juniper PointAmy Conrad(858)
914-1962media@prometheusbiosciences.com
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Apr 2024 to May 2024
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From May 2023 to May 2024